36 results
6-K
EX-99.1
GLPG
Galapagos NV
28 May 21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
6:00am
investigating patient and physician attitudes to setting treatment target goals in RA, as a strategy for managing the disease (POS0305).
“At Galapagos, we …
Physician and Patient Attitudes towards Treat-to-Target, its Implementation and Stated Treatment Goals in Patients with Rheumatoid Arthritis in a Real
6-K
EX-99.1
GLPG
Galapagos NV
7 Feb 22
Current report (foreign)
2:40pm
of disease and reporting of subjective measures alongside objective measures can be equally important in setting treatment goals to improve outcomes … with treatment goals in IBD: The modern Icarus?
Session time: 16:00 – 17:20 CET
Presentation time: 16:40 – 16:50 CET
Efficacy and safety of filgotinib
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
specific goals for remuneration are: to offer competitive opportunities for talented individuals by benchmarking against appropriate peer groups … , as well as sustainable progress towards long-term strategic goals, taking into account the management of unforeseen developments and broader
6-K
EX-99.1
GLPG
Galapagos NV
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
to do so. To achieve our goals, our business operations need to run smoothly. I look forward with confidence to working on these 3 priorities
6-K
EX-99.1
GLPG
Galapagos NV
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
; in severe cases we aim to keep patients out of hospital and reduce the need for surgical procedures such as colectomies. Overall, our goals are to manage
6-K
EX-99.1
ghoava
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
w9gedpcgo
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
lshyu8fkp14uxx ftcw
31 Mar 23
Current report (foreign)
6:05am
6-K
EX-99.1
ysry8s56ug tu
4 Jun 21
SELECTION study on filgotinib in ulcerative colitis published in The Lancet
6:05am
6-K
EX-99.1
pimt d9ibfdd
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
33u d7tp3f
31 May 22
Current report (foreign)
1:39pm
6-K
EX-99.1
tkb zoaa1lc74c8bbdg
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
EX-99.6
t92s kh1lqlkfhd
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.3
q8kwe7pqz
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
2ez6frvv9ag4v
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
q10impy8m gh6urh0rf
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
c48imidod5lakp4 gh
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
6-K
EX-99.1
e95w5ykedss69i77id8
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.2
itnxatpqof m0
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
xgmkx5o51xpvy
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm